RVXCF.US Resverlogix Corp.

Healthcare Biotechnology USA Stocks
0.0500 USD
Close of Nov 15, 2026
0.0400 0.1000
Market cap
USD 17.2M
P/E
-
P/B
-
ROE
-
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.

Is RVXCF.US undervalued?

Graham number

The Graham number of Resverlogix Corp. cannot be estimated reliably (it needs positive earnings and book value).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

Resverlogix Corp. fundamental analysis

No fundamental analysis for Resverlogix Corp. yet.

Resverlogix Corp. stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About Resverlogix Corp.

Resverlogix Corp., a late-stage clinical biotechnology company, develops therapeutics for patients with chronic illnesses. Its lead drug is apabetalone (RVX-208), a small molecule selective bromodomain and extra-terminal inhibitor for patients with cardiovascular disease, chronic kidney disease, type 2 diabetes mellitus, low high-density lipoprotein, recent acute coronary syndrome, and post COVID-19 conditions. The company has a partnership with Eversana Life Science Service…

Full company profile